Skip to main content
. 2019 Aug 6;10(47):4907–4918. doi: 10.18632/oncotarget.27127

Figure 4. Sensitivity to other CDK4/6 inhibitors and molecular-targeted drugs and expression levels of cell-cycle regulatory agents.

Figure 4

Cell proliferation of MCF7-C6 (A) and RIBR (B) cell lines treated with palbociclib and abemaciclib for 3 days was measured relative to the negative control. The results are expressed as mean ± SD of three independent experiments; * P < 0.05. (C) Protein expression levels of cell-cycle regulatory agents in MCF7-C6 and (D) EDR1, EDR1 with 1000 nM ribociclib for 24 h (indicated by an arrow) and RIBR1,2 cell lines were analyzed using western blotting, with β-tubulin as a protein loading control.